Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PACB Stock Summary
Top 10 Correlated ETFs
PACB
In the News
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down
PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.
Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.35 per share a year ago.
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.
PacBio's (PACB) New Kits to Boost Its Revio Sequencing System
PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.
PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction
PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P.
PACB Financial details
PACB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.6 | 0.46 | 0.64 | 0.57 | 0.79 | |
Net income per share | -0.51 | 0.17 | -0.89 | -1.32 | -1.21 | |
Operating cash flow per share | -0.51 | 0.11 | -0.55 | -1.17 | -1.05 | |
Free cash flow per share | -0.53 | 0.11 | -0.58 | -1.25 | -1.09 | |
Cash per share | 0.45 | 3.21 | 5.13 | 3.44 | 2.49 | |
Book value per share | 0.36 | 1.94 | 3.88 | 2.51 | 2.77 | |
Tangible book value per share | 0.36 | 1.94 | -0.15 | -1.15 | -0.86 | |
Share holders equity per share | 0.36 | 1.94 | 3.88 | 2.51 | 2.77 | |
Interest debt per share | 0.55 | 0.27 | 4.78 | 4.33 | 3.61 | |
Market cap | 783.99M | 4.49B | 4.17B | 1.84B | 2.49B | |
Enterprise value | 796.56M | 4.21B | 4.66B | 2.47B | 3.24B | |
P/E ratio | -10.07 | 152.59 | -22.99 | -6.18 | -8.11 | |
Price to sales ratio | 8.63 | 56.87 | 31.92 | 14.31 | 12.41 | |
POCF ratio | -10.01 | 230.04 | -37.47 | -6.98 | -9.33 | |
PFCF ratio | -9.66 | 242.99 | -35.57 | -6.55 | -9.03 | |
P/B Ratio | 14.28 | 13.37 | 5.27 | 3.26 | 3.55 | |
PTB ratio | 14.28 | 13.37 | 5.27 | 3.26 | 3.55 | |
EV to sales | 8.76 | 53.36 | 35.7 | 19.24 | 16.17 | |
Enterprise value over EBITDA | -8 | -41.14 | -26.16 | -8.31 | -11.67 | |
EV to operating cash flow | -10.17 | 215.85 | -41.91 | -9.38 | -12.16 | |
EV to free cash flow | -9.82 | 228 | -39.78 | -8.81 | -11.77 | |
Earnings yield | -0.1 | 0.01 | -0.04 | -0.16 | -0.12 | |
Free cash flow yield | -0.1 | 0 | -0.03 | -0.15 | -0.11 | |
Debt to equity | 1.48 | 0.14 | 1.22 | 1.7 | 1.29 | |
Debt to assets | 0.55 | 0.11 | 0.48 | 0.54 | 0.52 | |
Net debt to EBITDA | -0.13 | 2.71 | -2.77 | -2.13 | -2.71 | |
Current ratio | 3.71 | 9.72 | 13.28 | 11.12 | 7.81 | |
Interest coverage | -38.51 | -390.96 | -14.22 | -20.75 | -21.64 | |
Income quality | 0.93 | 0.66 | 0.61 | 0.84 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.66 | 0.81 | 0.87 | 1.5 | 0.93 | |
Intangibles to total assets | 0 | 0 | 0.41 | 0.46 | 0.53 | |
Capex to operating cash flow | 0.04 | -0.05 | 0.05 | 0.06 | 0.03 | |
Capex to revenue | -0.03 | -0.01 | -0.05 | -0.13 | -0.04 | |
Capex to depreciation | -0.29 | -0.11 | -0.51 | -0.98 | -0.27 | |
Stock based compensation to revenue | 0.18 | 0.22 | 0.56 | 0.61 | 0.36 | |
Graham number | 2.03 | 2.72 | 8.82 | 8.64 | 8.67 | |
ROIC | -0.51 | -0.3 | -0.06 | -0.18 | -0.18 | |
Return on tangible assets | -0.53 | 0.07 | -0.15 | -0.31 | -0.37 | |
Graham Net | -0.04 | 2.88 | -0.69 | -1.75 | -1.41 | |
Working capital | 59.21M | 318.26M | 1.02B | 778.08M | 647.02M | |
Tangible asset value | 54.92M | 335.49M | -29.97M | -257.32M | -217.94M | |
Net current asset value | -12.02M | 276.26M | -110.26M | -349.19M | -302.66M | |
Invested capital | 1.48 | 0.14 | 1.22 | 1.7 | 1.29 | |
Average receivables | 11.93M | 16.05M | 20.54M | 21.51M | 27.7M | |
Average payables | 7.55M | 5.97M | 7.29M | 11.52M | 13.55M | |
Average inventory | 15.6M | 13.77M | 19.41M | 37.49M | 53.53M | |
Days sales outstanding | 61.31 | 77.9 | 67.79 | 53.44 | 66.65 | |
Days payables outstanding | 54.24 | 28.2 | 56.04 | 55.38 | 34.32 | |
Days of inventory on hand | 86.28 | 112.11 | 125.31 | 231.98 | 129.15 | |
Receivables turnover | 5.95 | 4.69 | 5.38 | 6.83 | 5.48 | |
Payables turnover | 6.73 | 12.94 | 6.51 | 6.59 | 10.63 | |
Inventory turnover | 4.23 | 3.26 | 2.91 | 1.57 | 2.83 | |
ROE | -1.42 | 0.09 | -0.23 | -0.53 | -0.44 | |
Capex per share | -0.02 | -0.01 | -0.03 | -0.08 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.12 | 0.16 | 0.19 | 0.22 | 0.22 | |
Net income per share | -0.35 | -0.34 | -0.28 | -0.26 | -0.31 | |
Operating cash flow per share | -0.27 | -0.39 | -0.17 | -0.26 | -0.22 | |
Free cash flow per share | -0.29 | -0.41 | -0.18 | -0.26 | -0.22 | |
Cash per share | 3.41 | 3.61 | 3.33 | 3.01 | 2.36 | |
Book value per share | 2.49 | 2.86 | 2.57 | 3 | 2.63 | |
Tangible book value per share | -1.14 | -0.53 | -0.71 | -0.64 | -0.82 | |
Share holders equity per share | 2.49 | 2.86 | 2.57 | 3 | 2.63 | |
Interest debt per share | 4.25 | 3.96 | 3.81 | 3.72 | 3.39 | |
Market cap | 1.85B | 2.8B | 3.32B | 2.13B | 2.62B | |
Enterprise value | 2.48B | 3.39B | 4.05B | 3.11B | 3.37B | |
P/E ratio | -5.79 | -8.63 | -11.87 | -7.96 | -7.99 | |
Price to sales ratio | 67.66 | 72.05 | 69.73 | 38.23 | 44.9 | |
POCF ratio | -30.56 | -29.6 | -79.47 | -32.67 | -45.49 | |
PFCF ratio | -28.19 | -28.48 | -75.37 | -32.26 | -43.94 | |
P/B Ratio | 3.29 | 4.05 | 5.17 | 2.79 | 3.74 | |
PTB ratio | 3.29 | 4.05 | 5.17 | 2.79 | 3.74 | |
EV to sales | 90.77 | 87.24 | 85.04 | 55.81 | 57.82 | |
Enterprise value over EBITDA | -32.61 | -47.05 | -64.96 | -48.16 | -39.06 | |
EV to operating cash flow | -41 | -35.84 | -96.92 | -47.69 | -58.57 | |
EV to free cash flow | -37.82 | -34.48 | -91.92 | -47.09 | -56.58 | |
Earnings yield | -0.04 | -0.03 | -0.02 | -0.03 | -0.03 | |
Free cash flow yield | -0.04 | -0.04 | -0.01 | -0.03 | -0.02 | |
Debt to equity | 1.7 | 1.38 | 1.47 | 1.24 | 1.29 | |
Debt to assets | 0.54 | 0.5 | 0.51 | 0.5 | 0.52 | |
Net debt to EBITDA | -8.3 | -8.19 | -11.7 | -15.17 | -8.73 | |
Current ratio | 11.12 | 14.16 | 12.76 | 11.31 | 7.81 | |
Interest coverage | -22.61 | -25.14 | -20.59 | -22.99 | -24.19 | |
Income quality | 0.72 | 1.08 | 0.6 | 0.97 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 1.56 | 1.26 | 0.97 | 0.85 | 0.76 | |
Intangibles to total assets | 0.46 | 0.43 | 0.44 | 0.49 | 0.53 | |
Capex to operating cash flow | 0.08 | 0.04 | 0.05 | 0.01 | 0.04 | |
Capex to revenue | -0.19 | -0.1 | -0.05 | -0.01 | -0.03 | |
Capex to depreciation | -1.12 | -0.82 | -0.47 | -0.15 | -0.11 | |
Stock based compensation to revenue | 0.66 | 0.46 | 0.38 | 0.35 | 0.28 | |
Graham number | 4.44 | 4.64 | 4.03 | 4.2 | 4.26 | |
ROIC | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | |
Return on tangible assets | -0.08 | -0.08 | -0.07 | -0.07 | -0.1 | |
Graham Net | -1.74 | -1.14 | -1.3 | -1.22 | -1.34 | |
Working capital | 778.08M | 914.55M | 864.48M | 806.53M | 647.02M | |
Tangible asset value | -257.32M | -127.87M | -177.75M | -161.94M | -217.94M | |
Net current asset value | -349.19M | -220.27M | -267.66M | -249.89M | -302.66M | |
Invested capital | 1.7 | 1.38 | 1.47 | 1.24 | 1.29 | |
Average receivables | 20.77M | 24.19M | 26.81M | 27.26M | 33.55M | |
Average payables | 12.44M | 14.71M | 16.95M | 16.31M | 15.58M | |
Average inventory | 46.94M | 56.17M | 64.78M | 67.93M | 62.47M | |
Days sales outstanding | 61.81 | 68.46 | 45.47 | 49.27 | 56.47 | |
Days payables outstanding | 48.73 | 53.71 | 46.4 | 38.36 | 28.63 | |
Days of inventory on hand | 204.13 | 191.36 | 189.99 | 162.56 | 107.72 | |
Receivables turnover | 1.46 | 1.31 | 1.98 | 1.83 | 1.59 | |
Payables turnover | 1.85 | 1.68 | 1.94 | 2.35 | 3.14 | |
Inventory turnover | 0.44 | 0.47 | 0.47 | 0.55 | 0.84 | |
ROE | -0.14 | -0.12 | -0.11 | -0.09 | -0.12 | |
Capex per share | -0.02 | -0.02 | -0.01 | 0 | -0.01 |
PACB Frequently Asked Questions
What is Pacific Biosciences of California, Inc. stock symbol ?
Pacific Biosciences of California, Inc. is a US stock , located in Menlo park of Ca and trading under the symbol PACB
Is Pacific Biosciences of California, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $11.88. The lowest prediction is $6 and the highest is $20
What is PACB stock prediction ?
What is Pacific Biosciences of California, Inc. stock quote today ?
Pacific Biosciences of California, Inc. stock price is $3.745 today.
Is Pacific Biosciences of California, Inc. stock public?
Yes, Pacific Biosciences of California, Inc. is a publicly traded company.